drugset / Trial / NCT05489237
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.
Timeline
- Start
- 2022-08-03
- Primary completion
- 2027-03-10
- Completion
- 2027-03-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IDRX-42 | Small molecule | — | Oral |